Trial Profile
A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Paclitaxel; Topotecan
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- 08 Mar 2023 Primary endpoint has not been met. (Overall Survival [ Time Frame: From entry into the study to death or the date of last contact, assessed up to 5 years ], as per published in the Gynecologic Oncology
- 08 Mar 2023 Results of Final survival analysis, published in the Gynecologic Oncology
- 31 Jul 2017 Results of the final pre-specified analysis, published in The Lancet.